Intratumoral characteristics of tumor and immune cells at baseline and on-treatment correlated with clinical responses to MPDL3280A, an engineered antibody against PD-L1

Por Kohrt, Holbrook, Kowanetz, Marcin, Gettinger, Scott, Powderly, John, Koeppen, Hartmut, Sosman, Jeffrey A, Cruz, Cristina, Xiao, Yuanyuan, Mokatrin, Ahmad, Fine, Gregg, Chen, Daniel S, Hodi, F Stephen
Publicado em 2013

Myeloid cell biology and inhibition of anti-tumor immune responses by MPDL3280A in urothelial bladder cancer

Por Xiao, Yuanyuan, Rabe, Christina, Kowanetz, Marcin, Powles, Thomas, Vogelzang, Nicholas J, Petrylak, Daniel P, Loriot, Yohann, Denker, Mitchell, Nakamura, Rin, Wu, Qun J, Sumiyoshi, Teiko, Boyd, Zachary, Teng, Siew-leng M, Shen, Xiaodong, Fine, Gregg, Chen, Daniel S, Hegde, Priti S
Publicado no J Immunother Cancer (2014)

Circulating and tumor-based biomarkers predict clinical activity in cancer patients treated with the engineered anti-PD-L1 antibody MPDL3280A

Por Kowanetz, Marcin, Rabe, Christina, Xiao, Yuanyuan, Wu, Qun J, Koeppen, Hartmut, Leddy, Cecilia, Patel, Rajesh D, Powderly, John, Kohrt, Holbrook, Gettinger, Scott, Soria, Jean-Charles, Herbst, Roy S, Desai, Rupal, Denker, Mitchell, Ruppel, Jane, Boe, Marigold, Nakamura, Rin, Fu, Ling, Sumiyoshi, Teiko, Mokatrin, Ahmad, Shen, Xiaodong, Fine, Gregg, Chen, Daniel S, Hegde, Priti S
Publicado no J Immunother Cancer (2014)

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

Por Herbst, Roy S., Soria, Jean-Charles, Kowanetz, Marcin, Fine, Gregg D., Hamid, Omid, Gordon, Michael S., Sosman, Jeffery A., McDermott, David F., Powderly, John D., Gettinger, Scott N., Kohrt, Holbrook E. K., Horn, Leora, Lawrence, Donald P., Rost, Sandra, Leabman, Maya, Xiao, Yuanyuan, Mokatrin, Ahmad, Koeppen, Hartmut, Hegde, Priti S., Mellman, Ira, Chen, Daniel S., Hodi, F. Stephen
Publicado no Nature (2014)